Featured

Vaccine with ICB sidekick unlock anti-melanoma T cell immunity

While personalized neoantigen vaccines have great potential, T cell responses induced by these vaccines often lack strength. Blass, Keskin, et al. aimed to improve T cell antitumor immunity by optimizing vaccine adjuvants and combining the vaccine...

Different tumour-resident memory T-cell subsets regulate responses to anti-PD-1 and anti-CTLA-4 cancer immunotherapies

Using the MC38 tumor model, Damei et al. showed that CD103+CD8 TRM cells are involved in responses to anti-PD-1 treatment, but not CTLA-4 blockade. The benefits of anti-PD-1 treatment were compromised...

Exercise-induced microbiota metabolite enhances CD8 T cell antitumor immunity promoting immunotherapy efficacy

Phelps et al. investigated mechanisms underlying the positive benefits of exercise on ICI efficacy. In preclinical melanoma, adenocarcinoma, and lymphoma models, exercise promoted functional changes i...

FcγRIIIa is a noncanonical costimulatory molecule for CD8 T cells

Kao et al. showed that at steady state, primary human T cells and T cells from FcγR-humanized mouse strains lacked FcγR expression, except for a small fraction of CD8+ T cells that expressed FcγRIIIa....

Human cancer-targeted immunity via transgenic hematopoietic stem cell progeny

To overcome the poor persistence and progressive loss of functionality of TCR-engineered T cells, in vivo, Nowicki et al. evaluated tandem treatment with autologous blood-derived T cells and hematopoi...

See all for this week

Previous Digests

Mutant p53 doesn’t just lose functions - it gains them

July 9, 2025

Mutations in the p53 gene are well known drivers of cancer due to the loss of tumor suppressor functions that are maintained by wild-type p53. However, in recent investigations, Mahat et al. found that a common mutant p53, p53R175H...

CD8s get by without a little help from their friends

July 2, 2025

During acute infections, the primary immune response depends on CD4+ T cells providing help to CD8+ T cells. However, many effector CD8+ T cells (Teff) can respond to pathogens independently of helper responses, but these cells respond poorly to...

PSGL-1: a novel immune checkpoint for phagocytosis

June 25, 2025

Tumor cells can evade immune detection through a wide range of mechanisms, not all of which are fully understood. In recent work by Zhong and Wang et al., P-selectin glycoprotein ligand 1 (PSGL-1) – a known molecule involved in...

See More Digests

Watch ACIR in action

In November 2019, ACIR received the Visionary Award from the Cambridge Chamber of Commerce.

Watch the 3-minute video explaining ACIR's mission and goal:

In September 2020, ACIR was featured in the documentary The American Dream on Bloomberg TV.

Watch the 6-minute segment on the story behind your favorite digest here:

Donate to support researchers

About ACIR

ACIR's mission is to fast-track cancer immunotherapy research by helping researchers stay on top of the new literature in this fast-moving and multifaceted field, fostering their creativity and productivity in bringing us ever closer to curing this deadly disease.

Ed Fritsch

Ute Burkhardt

Lauren Hitchings

Gaelle Llambi

Maartje Wouters

Alex Najibi

Katherine J. Turner

Stan Wolf

Paula Hochman

Shishir Pant

Nathan Suek

Morgan Janes

More About Us

TESTIMONIALS

I'm a big fan of ACIR. I enjoy their weekly newsletters with clear, concise, and insightful summaries, complemented by excellent images. I've even used the images in some of my presentations to explain complex cancer immunotherapy findings. In our rapidly evolving field, their reliable and well-curated updates are invaluable.

— Carl H. June, MD

Richard W. Vague Professor in Immunotherapy; Professor of PL&M; Director, Center for Cellular Immunotherapies; Director, Parker Institute for Cancer Immunotherapy; University of Pennsylvania Perelman School of Medicine. (Supporter since 2025).

Testimonials